Zhejiang Jolly Pharmaceutical (300181.SZ) has announced a pre-increase, with an expected net income of 2.95 to 3.1 billion yuan in the first half of the year, a year-on-year increase of 49.24% to 56.83%.
Zhejiang Jolly Pharmaceutical (300181.SZ) released its 2024 interim performance forecast, expecting net profit attributable to shareholders of the listed company...
Zhejiang Jolly Pharmaceutical: 2024 Interim Performance Forecast
Zhejiang Jolly Pharmaceutical (300181.SZ): Currently, more than 370 traditional Chinese medicine formula granule national and provincial standard filing varieties have been completed.
Zhejiang Jolly Pharmaceutical (300181.SZ) stated on the investor interaction platform on July 10 that there is no need to decoct traditional Chinese medicine granule formulas for consumption. The company has currently completed the filing of more than 370 varieties of traditional Chinese medicine granule formula national and provincial standards.
Retail Investors Who Hold 55% of Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181) Gained 6.5%, Insiders Profited as Well
Key Insights Zhejiang Jolly PharmaceuticalLTD's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public 43% of the business is he
Investors Aren't Buying Zhejiang Jolly Pharmaceutical Co.,LTD's (SZSE:300181) Earnings
Zhejiang Jolly Pharmaceutical Co.,LTD's (SZSE:300181) price-to-earnings (or "P/E") ratio of 25.7x might make it look like a buy right now compared to the market in China, where around half of the comp
Zuoli Pharmaceutical (300181.SZ): Currently, Bailing Capsule is mainly working online in various provinces
Gelonghui, May 29丨An investor asked Zoli Pharmaceutical (300181.SZ) on the investor interactive platform, “Has the company's product Bailing Capsule started to be produced and sold? What's the progress so far?” The company replied that Bailing Capsule is currently mainly engaged in networked work in various provinces. After the work on netting and packaging design is completed, the company will promote the listing and sales work as soon as possible.
Estimating The Intrinsic Value Of Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181)
Key Insights Using the Dividend Discount Model, Zhejiang Jolly PharmaceuticalLTD fair value estimate is CN¥17.32 Current share price of CN¥15.20 suggests Zhejiang Jolly PharmaceuticalLTD is potentia
Zuoli Pharmaceutical (300181.SZ): 2023 equity distribution 10 distribution of 4.5 yuan Equity Registration Date May 21
On May 15, Ge Longhui Pharmaceutical (300181.SZ) announced that the company's 2023 equity distribution plan is to distribute RMB 4.500,000 (tax included) to all shareholders for every 10 shares based on the company's current total share capital of 701,387,335 shares. The share registration date for this equity distribution is May 21, 2024; the exclusive dividend date is May 22, 2024.
Are Strong Financial Prospects The Force That Is Driving The Momentum In Zhejiang Jolly Pharmaceutical Co.,LTD's SZSE:300181) Stock?
Most readers would already be aware that Zhejiang Jolly PharmaceuticalLTD's (SZSE:300181) stock increased significantly by 22% over the past three months. Given the company's impressive performance,
Zuoli Pharmaceutical (300181.SZ): The conversion of Linglian granules to non-prescription drugs was approved
Gelonghui announced on April 2, Zuoli Pharmaceutical (300181.SZ). The company recently learned that according to the “Administrative Measures on the Classification of Prescription Drugs and Non-prescription Drugs (Trial)” (former Order No. 10 of the State Drug Administration), after organizational verification and review by the State Drug Administration, the company's exclusive variety of Linglian granules were converted from prescription drugs to non-prescription drugs.
Individual Investors Are Zhejiang Jolly Pharmaceutical Co.,LTD's (SZSE:300181) Biggest Owners and Were Hit After Market Cap Dropped CN¥638m
Key Insights The considerable ownership by individual investors in Zhejiang Jolly PharmaceuticalLTD indicates that they collectively have a greater say in management and business strategy The top 25
A-share afternoon review: The Shanghai index fell 0.47%, and traditional Chinese medicine, liquor, and low-altitude economic concepts rose the most
Major A-share indices had mixed ups and downs. As of the midday close, the Shanghai Index fell 0.47% to 3054.12 points, the Shenzhen Stock Exchange Index rose 0.05%, and the GEM index rose 0.22%.
Zuoli Pharmaceutical (300181.SZ) Performance Report: Net profit of 386 million yuan in 2023 increased 41.55% year-on-year
Gelonghui, March 11 | Zuoli Pharmaceutical (300181.SZ) announced its 2023 annual performance report. During the reporting period, the company achieved total operating income of 1,942 million yuan, an increase of 7.61% over the same period of the previous year; achieved total profit of 453 million yuan, an increase of 39.06% over the same period of the previous year; realized net profit attributable to shareholders of listed companies of 386 million yuan, an increase of 41.55% over the same period last year; net profit attributable to listed shareholder companies after deducting non-recurring profit and loss of 375 million yuan Yuan, a year-on-year increase of 41.5
Zuoli Pharmaceutical (300181.SZ): Lingze tablets received the “Certificate of Protected Varieties of Traditional Chinese Medicine”
Gelonghui, March 7, 丨 Zuoli Pharmaceutical (300181.SZ) announced that recently, Zhejiang Zuoli Pharmaceutical Co., Ltd. received the “Chinese Medicine Protected Variety Certificate” from the State Drug Administration. The company's exclusive variety, Lingze tablets, was listed as a national second-class protected traditional Chinese medicine. The certificate number: (2024) Sinopharm Guarantee No. 002. The protection period is from March 1, 2024 to March 1, 2031. As one of the important products in the Wuling series, Lingze tablets are an exclusive innovative drug for treating symptoms such as benign prostatic hyperplasia and frequent nocturnal urination. It is a national drug catalogue product and national medical insurance catalogue B
Zhejiang Jolly Pharmaceutical Co.,LTD's (SZSE:300181) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181) shares have had a really impressive month, gaining 26% after a shaky period beforehand. The bad news is that even after the stocks recovery in th
Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) Stock Performs Better Than Its Underlying Earnings Growth Over Last Three Years
By buying an index fund, you can roughly match the market return with ease. But if you pick the right individual stocks, you could make more than that. Just take a look at Zhejiang Jolly Pharmaceuti
Zuoli Pharmaceutical (300181.SZ): Participated in the Beijing-Tianjin-Hebei “3+N” Alliance Drug Centralized Procurement Selection
Gelonghui, Feb. 28, 丨 Zuoli Pharmaceutical (300181.SZ) announced that the company and its holding subsidiary Qinghai Zhufeng Cordyceps Sinensis Pharmaceutical Co., Ltd. participated in the centralized procurement of drugs in the Beijing-Tianjin-Hebei “3+N” Alliance. According to the “Notice on Accomplishing the Implementation of the Ninth Batch of National Organization Collection and Beijing-Tianjin-Hebei “3+N” Alliance Drug Centralized Procurement Results” issued by the Tianjin Municipal Medical Security Bureau on February 27, 2024, the company's products, Wuling capsules, were selected for this volume procurement.
Is Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Zuoli Pharmaceutical (300181.SZ): Striving to turn the Wuling series into a family of 10 products in the future
Gelonghui, Feb. 1 | Zuoli Pharmaceutical (300181.SZ) was recently surveyed by investors on “How is the development progress of the company's other products in the Wuling series?” The company replied that the company now has 3 exclusive products in the Wuling series: Wuling capsules, Lingze tablets, and Linglian granules. In addition, the company is currently developing the new drug Reishi tablets, which also use Wuling bacteria powder to guide the formulation of traditional Chinese medicine to treat modern diseases. It is an innovative class of traditional Chinese medicine. It has now completed pre-clinical research. In the future, the company will continue to develop new products in the exclusive Wuling series based on Wuling bacteria powder and prescriptions from famous doctors
Zuoli Pharmaceutical (300181.SZ): Linglian granules are not covered by national health insurance, and the company has converted them to OTC varieties
Gelonghui February 1 丨 Zuoli Pharmaceutical (300181.SZ) was recently surveyed by investors on “What are the company's plans for Linglian granules?” The company replied that Linglian powder is part of the company's Wuling series of products. It is a compound formulation developed around Wuling bacteria powder under the theoretical guidance of traditional Chinese medicine. It is dedicated to comprehensively improving the symptoms of menopause in women and paying more attention to the mood and sleep of menopausal women. Clinically, the therapeutic effect is obvious, and it has already entered the “Guidelines for Clinical Application of Proprietary Chinese Medicine in the Treatment of Menopausal Syndrome”. Linglian granules are not covered by national health insurance, and the company has switched to OTC varieties. Currently
No Data